Are We Measuring What Matters Most in ITP? – ITP Australia and New Zealand
ITP Australia and New Zealand shared a post on LinkedIn:
“Are we measuring what matters most in ITP?
Historically, the management of Immune Thrombocytopenia (ITP) has focused heavily on readily quantifiable outcomes such as platelet counts and bleeding events.
Yet for many patients, these measures tell only part of the story.
In a recent interview discussing quality-of-life data from the phase 2 mezagitamab study presented at ISTH 2026, International ITP Medical Advisor Dr David Kuter highlights the importance of evaluating outcomes that directly affect patients’ daily lives, including fatigue, physical functioning, psychological wellbeing, and overall quality of life.
One of the key messages from the discussion is that ‘ITP is not just the platelet count.’
The study demonstrated meaningful improvements across multiple patient-reported outcome measures, reinforcing the growing recognition that successful ITP management involves more than achieving a numerical platelet target.
As the field continues to evolve, incorporating patient-reported outcomes into research, clinical practice, and treatment decision-making will be critical to ensuring care reflects what matters most to patients.
How can we better integrate quality-of-life measures into routine ITP care and treatment evaluation?”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?